Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.
Tanox Inc (under license from Biogen Idec, formerly Biogen Inc) is developing ibalizumab, an intravenous, humanized, monoclonal antibody specific for CD4, for the potential treatment of HIV infection. In August 2006, the FDA advised Tanox to conduct additional dose-finding studies, from which data could potentially be used in a BLA filing. Ibalizumab had reached phase II clinical trials; however, there are currently no ongoing clinical trials.
Profectus BioSciences Inc, Techcenter at UMBC, Room 4011, 1450 South Rolling Road, Baltimore, MD 21227, USA. dimitrov@profectusbiosciences.com
Anthony
A
Dimitrov
D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000276:immunology*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D013329:Structure-Activity Relationship
D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; C481504:ibalizumab